He joined Jitsubo and became CEO in December 2021. As low molecule API process development and CMC veteran for more than 30 years, he served key positions in the pharmaceutical industry and joined Takeda Pharmaceutical Industries in 1990. Prior to Jitsubo, he was CTO of SPERA PHARMA Inc. (2021), General Manger of Drug Manufacturing Research (2017), R&D Director for global API process development at Takeda (2012), Global CMC leader for several API process development at Takeda (2007).
He was a visiting scientist to Queens University, Canada (2001) and obtained his PhD from Osaka City University(2008).
He joined Jitsubo in 2017 as a board member and became Executive Vice President in December 2019. Prior to Jitsubo, he held management positions in companies, Director, Universal Materials Incubator (2015), CTO, Inoac Corporation (2006), Chairman, Microhard Corporation(2004), President, JASDIC Park Co. (1997), President, KK Raychem (1886) and VP, Celanese Japan (1983). He also worked as a management consultant at McKinsey Inc, (1977) and project manager at JGC Corporation after he obtained chemical engineering degree from Waseda University (1964)
Kazuaki Kanai, Ph.D.
Jitsubo CO., LTD.
|Board Director & CSO, ASTENA Holdings Co., Ltd.
Chairperson & Representative Director, SPERA PHARMA, Inc.
|Audit & Supervisory Board Member,
ASTENA Holdings Co., Ltd.
Audit & Supervisory Board Member, SPERA PHARMA, Inc.
|Company Name||Jitsubo CO., LTD.|
|Address||Life Science Research Center 4-1 1-1-43 Suehiro-cho, Tsurumi, Yokohama, Kanagawa-pref. 230-0045 Japan|
|Founded||April 8, 2005|
|Equity Capital||10,000,000 JPY|
Development of peptide manufacturing process, Molecular Hiving ™
Contract manufacturing of APIs and Licensing